Last week we discussed how to determine where your company fits within your marketplace. Once you have completed that process, the next step in a fundraising campaign is to develop your marketing materials. In this week’s edition of the summer reading series, we describe the importance of and what constitutes a strong set of marketing materials in the life science fundraising world. While your team and your technology are what will ultimately secure an allocation, having marketing collateral that clearly and concisely communicates your message will help you tremendously in getting in the door with investors.
Chapter 6 of The Life Science Executive’s Fundraising Manifesto discusses in depth the different pieces of marketing collateral you should be putting into the marketplace and how to develop everything from your logo to your pitch deck.
A medical products corporation headquartered in Europe is focused on flexible endoscopy for gastroenterology and urology as well as hospital supplies. The firm is seeking to in-license approved or close-to-approval products from across the globe; growth capital investment would also be considered. Currently the firm is interested in products with large potential in EU and Asia markets.
For in-licensing opportunities, the firm is focused on gastroenterology and urology, including bladder, kidney, prostate, and incontinence illnesses. The firm considers therapeutic devices and diagnostic tools, mainly for flexible endoscopy. The firm is most interested in products that have received or are close to receiving regulatory approval such as a CE mark.
The firm is looking for experienced management teams with sector expertise.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
An NJ-based venture investment firm focused on bridging Eastern and Western innovations and investment opportunities invests in early to mid-stage biopharma and medtech projects. With its own R&D facilities in China, in-licensing assets from the U.S. and Europe to China would be a consideration for their investment opportunities. With additional strategic investing partners in China, the size of investment can vary depending on the deal. The firm is currently looking for new opportunities globally.
The firm is interested in preclinical to phase 1/2 stage assets in biotech and medtech. The firm is open to all therapeutic modalities. Within medtech, the firm is more interested in personalized medicine/companion diagnostics and novel devices. In terms of disease areas, the firm is most interested in chronic diseases, liver and gastrointestinal conditions, but the firm generally avoids behavioral illnesses.
The firm is seeking strong management teams with products that could address large unmet medical need. The firm has R&D facilities in China that can facilitate product development and registration both for China local and global market. The firm is open to negotiate regional rights with flexible terms.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
A venture fund headquartered in Cambridge, MA makes Series A-stage investments of $200 K – $500 K. Follow on funding is coordinated through syndication and can range from $0.5 – 5 M. The firm focuses on the healthcare IT, digital health, and suppliers and engineering sectors, and prefers companies located in the US. Companies should be in the early stages of revenue production and exhibit some market traction and potential for global expansion. The firm will make about 6 new investments over the next 12 months.
The firm looks for enterprise technology plays that incorporate proprietary algorithms for data mining, machine learning, connected devices, virtual reality, and other technologies to create new systems. Past investments include biomedical and genomics data analytics platforms. They would consider wearable or medical devices that incorporate sophisticated software or connectivity.
The firm seeks experienced management teams with a vision for the future. The firm can take a board seat when they have specific expertise in the area, and does not have an equity target. Initial revenue generation and evidence of market strength is desired.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
The corporate venture capital arm of a global pharmaceutical company invests to further its’ parent company’s future strategic position, rather than purely for financial returns. The firm looks to make equity investments into emerging biotech and pharmaceutical companies ranging from a few hundred thousand to $6 million in the initial round, with additional capital reserved for follow on investments. The firm has no set allocations it plans to make over the next year but is actively reviewing new opportunities. The firm considers opportunities located around the globe.
The firm is looking for biopharmaceutical companies developing therapeutics and therapeutic platforms at any stage of development and is open to considering both small molecules, biologics, nucleic acid, and gene and cellular therapeutic approaches. The firm is interested in immunology, neuroscience, oncology as well as other opportunistic areas that can benefit its parent company.
The firm is looking for companies with experienced management teams with domain expertise. The firm strongly prefers board representation following investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
The first Redefining Early Stage Investments (RESI) Conference took place on September 16, 2013, and three years later, following highly successful events in San Francisco, Houston and Toronto, RESI will return to Boston for the 10th RESI Conference. Life Science Nation will be hosting the RESI Boston conference in collaboration with Johnson & Johnson Innovation, JLABS on September 13th, 2016.
RESI Boston is a venue for entrepreneurs to meet with 10 categories of investors that LSN tracks including Family Offices, Corporate Venture Funds, Angel Groups, Venture Philanthropy, Venture Capital and more. Through the RESI Partnering, fundraising executives can have up to 16 scheduled meetings as well as many more ad-hoc meetings with diverse life science investors who fit their company’s technology sector, indication and stage of development. Additionally, through an expansive series of panels and workshops, attendees will have the chance to hear firsthand accounts from investors explaining their current investment mandates and process for identifying and qualifying candidates.
Last week at RESI on MaRS, the MaRS HealthKick Innovation Challenge showcased 30 companies from the digital health, biotech, medical device and diagnostics sectors. These companies were screened and selected from over a hundred applicants; all were very strong competitors, but only one winner could emerge from the all-day exhibition-style contest. Here are the top 4 entrants, with a tie for third place!
First Place: Perimeter Medical Imaging (Toronto, Canada)
Complimentary tickets to 3 RESI Conference Series events (2 tickets per event) and a GoPro Camera sponsored by MedMarc
Perimeter Medical Imaging develops, patents, and commercializes advanced surgical imaging tools that allow surgeons, radiologists and pathologists to better assess microscopic tissue structures during surgical procedures. Perimeter’s Optical Tissue Imaging System (OTIS™) is the only solution that provides clinicians with an ultra-high resolution image of the entire surface of an excised tissue specimen, providing accurate information in real time, and enabling better surgical decisions and outcomes.
Michael Quigley, VP of Market Research, Life Science Nation Paul Weber, President and CEO, Perimeter Medical Imaging Lynn Carney, Manager, Marketing Dept, Medmarc Insurance Group
Second Place: BresoTec Inc. (Toronto, Canada)
Complimentary tickets to 2 RESI Conference Series events (2 tickets per event)
BresoTec Inc., a Canadian company based in Toronto, Ontario, develops, manufactures and sells products for the diagnosis and treatment of sleep disorders. BresoTec was founded by UHN (University Health Network) and MaRS Innovation.
BresoTec’s first product, BresoDx®, is an innovative device using proprietary acoustic and movement recording technology as an aid in the diagnosis of sleep apnea.
BresoDx® is a cordless, battery operated device that patients can use at home, in their own bed. The accuracy of BresoDx® versus the PSG standard has been tested and validated in several clinical trials led by Drs. Hisham Alshaer and Douglas Bradley of the University Health Network. Such accuracy in a simple, cordless device establishes BresoDx® as an accurate, easy-to-use and cost-effective home sleep test for physicians, patients and health care providers as an aid in the diagnosis of sleep apnea.
Julie Brogren, COO & VP of Global Sales and Marketing, Bresotec Inc. Michael Quigley, VP of Market Research, Life Science Nation Caren Cao, International Business Liaison, Bresotec Inc.
Third Place (Tie): QoC Health (Toronto, Canada)
Complimentary tickets to 1 RESI Conference Series event (2 tickets)
QoC Health is a Certified B Corp enabling patient centered care with mobile solutions, new service delivery models, and cloud computing. QoC Health’s Cloud Connect platform is a healthcare API (or digital spine) on which health tools are added, including post-surgery discharge monitoring, wound care, transitions in care, and decision aids.
QoC Health’s tools are co-designed with patients and clinicians to maximize user experiences. With best-in-class security and privacy, the company’s solutions can interact on a two-way basis with electronic medical records and personal health records to maximize information sharing. The solutions improve patient outcomes and reduce costs for healthcare providers.
Raymond Shih, President & Co-Founder, QoC Health Michael Quigley, VP of Market Research, Life Science Nation
Third Place (Tie): Woven Orthopedic Technologies (Manchester, CT)
Complimentary tickets to 1 RESI Conference Series event (2 tickets)
Woven Orthopedic Technologies is a medical device business that designs and develops orthopedic technologies to treat the rapidly aging global population affected by orthopedic conditions. Their premier technology addresses the #1 problem with the #1 technology used in orthopedics today by enhancing screw fixation in patients who receive treatment for fractures.
Today, the company operates at the core of the intersection between science, technology, and medicine by leveraging advances in smart engineered bio-textiles to design technologies that help provide better care for less cost, to more people around the world.
Michael Quigley, VP of Market Research, Life Science Nation Ilana Odess, CEO, Woven Orthopedic Technologies
Thank you to all who competed in the MaRS HealthKick Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies. If you’d like to be part of the RESI Boston Innovation Challenge, apply now.
